2-benzyl-N-(4-fluorobenzyl)-2-methylmalonamic acid | 1193364-91-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-benzyl-N-(4-fluorobenzyl)-2-methylmalonamic acid
• 英文别名: 2-Benzyl-3-[(4-fluorophenyl)methylamino]-2-methyl-3-oxopropanoic acid
• CAS: 1193364-91-8
• 化学式: C₁₈H₁₈FNO₃
• 分子量: 315.344
• InChiKey: KXCGTYTVUGBXJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyl-N-(4-fluorobenzyl)-2-methylmalonamic acid 在 盐酸 、 三乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.5h， 生成 2-benzyl-N-(4-fluoro-benzyl)-2-methyl-N'-trityloxymalonamide
  参考文献：
  名称：

  Structure–Activity Relationships and Blood Distribution of Antiplasmodial Aminopeptidase-1 Inhibitors

  摘要：

  Malaria is a severe infectious disease that causes between 655 000 and 1.2 million deaths annually. To overcome the resistance to current drugs, new biological targets are needed for drug development. Aminopeptidase M1 (PfAM1), a zinc metalloprotease, has been proposed as a new drug target to fight malaria. Herein, we disclosed the structure-activity relationships of a selective family of hydroxamate PfAM1 inhibitors based on the malonic template. In particular, we performed a "fluoro-scanning" around hit 1 that enlightened the key positions of the halogen for activity. The docking of the best inhibitor 2 is consistent with in vitro results. The stability of 2 was evaluated in microsomes, in plasma, and toward glutathione. The in vivo distribution study performed with the nanomolar hydroxamate inhibitor 2 (BDM14471) revealed that it reaches its site of action. However, it fails to kill the parasite at concentrations relevant to the enzymatic inhibitory potency, suggesting that killing the parasite remains a challenge for potent and druglike catalytic-site binding PfAM1 inhibitors. In all, this study provides important insights for the design of inhibitors of PfAM1 and the validity of this target.

  DOI：

  10.1021/jm301506h
• 作为产物：
  描述：

  2-benzyl-2-methylmalonic acid diethyl ester 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-benzyl-N-(4-fluorobenzyl)-2-methylmalonamic acid
  参考文献：
  名称：

  Structure–Activity Relationships and Blood Distribution of Antiplasmodial Aminopeptidase-1 Inhibitors

  摘要：

  Malaria is a severe infectious disease that causes between 655 000 and 1.2 million deaths annually. To overcome the resistance to current drugs, new biological targets are needed for drug development. Aminopeptidase M1 (PfAM1), a zinc metalloprotease, has been proposed as a new drug target to fight malaria. Herein, we disclosed the structure-activity relationships of a selective family of hydroxamate PfAM1 inhibitors based on the malonic template. In particular, we performed a "fluoro-scanning" around hit 1 that enlightened the key positions of the halogen for activity. The docking of the best inhibitor 2 is consistent with in vitro results. The stability of 2 was evaluated in microsomes, in plasma, and toward glutathione. The in vivo distribution study performed with the nanomolar hydroxamate inhibitor 2 (BDM14471) revealed that it reaches its site of action. However, it fails to kill the parasite at concentrations relevant to the enzymatic inhibitory potency, suggesting that killing the parasite remains a challenge for potent and druglike catalytic-site binding PfAM1 inhibitors. In all, this study provides important insights for the design of inhibitors of PfAM1 and the validity of this target.

  DOI：

  10.1021/jm301506h

文献信息

• Hydroxamates: Relationships between Structure and Plasma Stability
  作者：Marion Flipo、Julie Charton、Akila Hocine、Sandrine Dassonneville、Benoit Deprez、Rebecca Deprez-Poulain

  DOI：10.1021/jm900648x

  日期：2009.11.12

  display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure−plasma stability for hydroxamates

  异羟肟酸酯是用于化学生物学的有价值的工具，也是用于药物化学的有趣线索。尽管许多异羟肟酸酯显示出对金属蛋白酶的纳摩尔活性，但只有三种异羟肟酸酯进入市场，其中包括HDAC抑制剂伏立诺他。开发失败通常归因于缺乏选择性，毒性或稳定性差。为了帮助药用化学家进行血浆稳定性方面的研究，我们对异羟肟酸酯的结构-血浆稳定性进行了首次和初步研究。我们定义一些结构规则，以预测或改善临床前阶段的血浆稳定性。